Abstract 291P
Background
Malnutrition is one of the most frequent disorders in cancer patients which accounts for 50-90%. This high prevalence of malnutrition is very concerning as it is associated with reduced treatment efficacy, functional status, quality of life and survival. The prevalence of malnutrition varies with tumor type, site and the stage of the disease. The highest prevalence of cancer patients with nutritional deficits is seen in those with tumors of the gastrointestinal tract and lung.
Methods
It is a hospital based cross sectional study among 95 cancer patients. They were screened using Patient Generated Subjective Global Assessment (PGSGA) for malnutrition. Median and IQR were used to describe the continuous data and frequency and percentage for the categorical variables. To identify the correlation between continuous variables, Pearson’s correlation coefficient was used. At 95% confidence interval, p value less than 0.05 was termed as statistically significant. The data were analyzed using SPSS 20.0 software.
Results
Among 95 patients, 36.85% of patients were GI cancers followed by 27.37% lung cancer, breast cancer (10.53%) and rectal cancer (10.53%). Most of the patients (81.05%) were well nourished Subjective Global Assessment (SGA-A), 13.68% patients were moderately malnourished or had suspected malnutrition (SGA-B) and 5.26% patients were severely malnourished (SGA-C). There was statistically significant difference in association of malnutrition with gastrointestinal cancer. Among equally distributed limited and metastatic cancers, there was no significant association between stages of cancer with malnutrition.
Conclusions
Nutritional assessment and support should be an integral part of care in gastrointestinal cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
303P - Long-term oncologic outcomes for patients undergoing volatile versus intravenous anesthesia for non-small cell lung cancer surgery
Presenter: Ji Hyung Hong
Session: Poster viewing 04
306P - Multimodal management and outcomes of stage III non-small cell lung cancer: KINDLE-Egypt analysis
Presenter: Rasha Aboelhassan
Session: Poster viewing 04
307P - Differential expression profiling of transcripts in stage IIIA non-small cell lung cancer (NSCLC) of smokers and non-smokers cases of north India: A geneto-environmental study
Presenter: Archana Mishra
Session: Poster viewing 04
308P - Phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study)
Presenter: Masanao Nakashima
Session: Poster viewing 04
309P - Pneumonitis and corticosteroid treatment in patients with unresectable non-small cell lung cancer receiving durvalumab consolidation after definitive chemoradiotherapy
Presenter: Saori Murata
Session: Poster viewing 04
311P - Cost-effectiveness of alectinib compared with chemotherapy in first-line treatment for anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer in Thailand
Presenter: Sermsiri Sangroongruangsri
Session: Poster viewing 04
312P - ClinMatch: A clinical trial matching platform that improves trial accessibility among NSCLC patients through comprehensive genomic and clinical profiling
Presenter: Allen Chi Shing Yu
Session: Poster viewing 04
313P - A pool analysis of MET TKI SCC244 in NSCLC patients with MET overexpression
Presenter: Yongfeng Yu
Session: Poster viewing 04